Paper
| Ultra Sensitive Cytokine Quantification | |
| Imperacer® (Immuno-PCR) Method Development and Validation for Ultra Sensitive Quantification of Interferon Gamma in Human Plasma to Support Clinical Phase I of a Cancer Vaccine Candidate | request reprint |
| Highly Sensitive Cytokine Quantification using Imperacer®, an Immuno-PCR based Ligand-Binding Assay System | request reprint |
| Development and Validation of an Ultra Sensitive Imperacer (Immuno-PCR) Method for Quantification of Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) | request reprint |
| Clinical Biomarker Quantification: Novel Tools for Pharmacodynamic Applications | |
| Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technologies Evaluation | request reprint |
| Detecting Antigens by Quantitative Immuno-PCR | request reprint |
| An Ultra Sensitive Immuno-qPCR Assay for Quantitation of Intact Pegylated Interferon Beta-1a in Human Serum | request reprint |
| Feasibility of Combinatorial Chemokine Arrays to Study Blood and CSF in Multiple Sclerosis | |
| Imperacer® pTau Microsampling Bioanalytical Approach Supports Transgenic Mouse CSF Measurement | request reprint |
| Ultrasensitive Multiparameter Biomarker Quantification in Microsampling Support | |
| Ultrasensitive Biomarker Quantification in Dried Blood Spot Samples | request reprint |
| Technology Comparison of Two Ligand-Binding Assay Platforms for Anti-Drug-Antibody Sample Testing Support for a Non-disclosed Lead Compound: MSD vs. Imperacer | request reprint |
| Immuno-PCR (IPCR) as Novel Tool for Improvement of Drug Tolerance in Immunogenicity Testing | |
| From ELISA to a Novel Immuno-PCR (I-PCR) based Immunogenicity Assay in Quest to Improve the Drug Tolerance | request reprint |
| Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes | |
| Immuno-PCR Assays for Immunogenicity Testing | |
| Feasibility of Immuno-PCR Technology Platforms as an Ultra Sensitive Tool for the Detection of Anti-Drug Antibodies |
| Selection of Critical Reagents for Development of an Ultra Sensitive Immuno-PCR Based Method for Detection of Botulinum Toxin-A in Several Matrices | request reprint |
| Randomized Phase I Trial of the Safety/Tolerability of Anti-Lingo-1 mAB BIIB033 | |
| Phase-I “Proof of Principle”: Immunization with Virosome-Gp41-Derived Antigen Induces Mucosal Antibodies with Antiviral Properties to Reduce Risk of HIV-1 Infection | request reprint |
| Development of an Imperacer Method for Clinical Phase 1a Human Trial of ShK-186, a Specific and Potent Peptide Inhibitor of the Kv1.3 Potassium Channel | |
| Development of an Immuno-PCR Method with Extreme Robustness against the Presence of Endogenous Counterpart for Clinical PK Study Bioanalytical Support of Replacement Therapy Fc-fusion Protein | request reprint |
| Development and GLP-Validation of Imperacer® (Immuno-PCR) Methods for Ultra Sensitive Quantification of Mucosal Antibodies in Support of Phase-I Clinical Trial for a Novel Vaccination Strategy in Preventing HIV Infection | request reprint |
| Comparison of Two Immunoassay Technology Platforms for Bioanalytical Sample Testing Support in PK Profiling of a Non-disclosed Lead Candidate in Diabetes: ELISA vs. Imperacer | request reprint |
| Pharmacokinetics of Natural Mistletoe Lectins after Subcutaneous Injection | |
| Adaptation and Performance of an Immuno-PCR Assay for the Quantification of Aviscumine in Patient Plasma Samples |
| Phase-I “Proof of Principle”: Immunization with Virosome-Gp41-Derived Antigen Induces Mucosal Antibodies with Antiviral Properties to Reduce Risk of HIV-1 Infection | request reprint |
| Development and GLP-Validation of Imperacer® (Immuno-PCR) Methods for Ultra sensitive Quantification of Mucosal Antibodies in Support of Phase-I Clinical Trial for a Novel Vaccination Strategy in Preventing HIV Infection | request reprint |
| Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes | |
| New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes | request reprint |
| Ultra Sensitive Cytokine Quantification | |
| Imperacer® (Immuno-PCR) Method Development and Validation for Ultra Sensitive Quantification of Interferon Gamma in Human Plasma to Support Clinical Phase I of a Cancer Vaccine Candidate | request reprint |
| Highly Sensitive Cytokine Quantification using Imperacer®, an Immuno-PCR based Ligand-Binding Assay System | request reprint |
| Development and Validation of an Ultra Sensitive Imperacer (Immuno-PCR) Method for Quantification of Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) | request reprint |
| Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technology Evaluation | request reprint |
| An Ultrasensitive Immuno-qPCR Assay for Quantitation of Intact Pegylated Interferon Beta-1a in Human Serum | request reprint |
| Clinical Biomarker Quantification: Novel Tools for Pharmacodynamic Applications | |
| Challenges in Developing a Sensitive PD Assay–From Tool Selection to Technologies Evaluation | request reprint |
A broader scope of Imperacer case studies and peer-reviewed publications are available upon request.
Please feel free to contact Chimera Biotec’s team of dedicated scientists for more in-depth information. We are looking forward to provide you with the immunoassay to exceed your highest expectations.